ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,930.85
1.09%
Dow Jones
42,840.26
1.18%
US Dollar vs MXN
20.0813
0.00%
Brent Oil
72.72
0.00%
Bitcoin
97,121.47
-0.09%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Lucid Diagnostics Inc (LUCD) Cotización

Lucid Diagnostics Inc

Lucid Diagnostics Inc (LUCD)

NASDAQ
0.781
0.0101
(1.31%)
Cerrado 22 Diciembre 3:00PM
Delayed by 15 minutes
0.78
-0.001
(-0.13%)
Fuera de horario: 6:31PM
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
0.78
Postura de Compra
0.78
Postura de Venta
1.50
Volume Operado de la Acción
374,390
0.78 Rango del Día 0.7999
0.6301 Rango de 52 semanas 1.58
Capitalización de Mercado [m]
46.287M
Precio Anterior
0.7709
Precio de Apertura
0.79
Hora
1
@
0.795
Última hora de negociación
Volumen financiero
US$ 295,079
Precio Promedio Ponderado
0.788158
Volumen promedio (3 m)
455,496
Acciones en circulación
59,342,479
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.88
Beneficio por acción (BPA)
-0.89
turnover
2.43M
Beneficio neto
-52.67M

Acerca de Lucid Diagnostics Inc

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically hig... Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard. Mostrar más

Sector
Surgical,med Instr,apparatus
Industria
Surgical,med Instr,apparatus
Sede
Wilmington, Delaware, USA
Fundado
-
Lucid Diagnostics Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker LUCD. The last closing price for Lucid Diagnostics was US$0.77. Over the last year, Lucid Diagnostics shares have traded in a share price range of US$ 0.6301 to US$ 1.58.

Lucid Diagnostics currently has 59,342,479 shares in issue. The market capitalisation of Lucid Diagnostics is US$45.75 million. Lucid Diagnostics has a price to earnings ratio (PE ratio) of -0.88.

LUCD Últimas noticias

Más noticias

Form 8-K - Current report

20 Diciembre 2024
Edgar (US Regulatory)

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters PR Newswire NEW YORK, Dec. 19, 2024 Partnership launched with fully-contracted...

19 Diciembre 2024
PR Newswire (US)

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Dec. 11, 2024 Study demonstrates outstanding...

11 Diciembre 2024
PR Newswire (US)

Form D - Notice of Exempt Offering of Securities

06 Diciembre 2024
Edgar (US Regulatory)

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones PR Newswire NEW YORK, Dec. 3, 2024 New convertible debt...

03 Diciembre 2024
PR Newswire (US)

Form 8-K - Current report

29 Noviembre 2024
Edgar (US Regulatory)

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test PR Newswire NEW YORK, Nov. 20, 2024 NEW YORK, Nov. 20, 2024 /PRNewswire/...

20 Noviembre 2024
PR Newswire (US)

Form 8-K - Current report

18 Noviembre 2024
Edgar (US Regulatory)

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum PR Newswire NEW YORK, Nov. 18, 2024 NEW YORK, Nov. 18, 2024 /PRNewswire/...

18 Noviembre 2024
PR Newswire (US)

PAVmed Provides Business Update and Third Quarter 2024 Financial Results

PAVmed Provides Business Update and Third Quarter 2024 Financial Results PR Newswire NEW YORK, Nov. 14, 2024 Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence...

14 Noviembre 2024
PR Newswire (US)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1000.780.830.76025209210.79560822CS
4-0.2-20.40816326530.981.020.7536258210.87380448CS
12-0.006-0.7633587786260.7861.120.7534554960.91240151CS
260.0913.04347826090.691.120.6813089800.88347638CS
52-0.51-39.53488372091.291.580.63012320940.92230877CS
156-4.15-84.17849898584.935.870.63011430661.67015911CS
260-11.97-93.882352941212.7513.50.63011532092.59052651CS

LUCD - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Lucid Diagnostics?
El precio actual de las acciones de Lucid Diagnostics es US$ 0.78
¿Cuántas acciones de Lucid Diagnostics están en circulación?
Lucid Diagnostics tiene 59,342,479 acciones en circulación
¿Cuál es la capitalización de mercado de Lucid Diagnostics?
La capitalización de mercado de Lucid Diagnostics es USD 45.75M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Lucid Diagnostics?
Lucid Diagnostics ha negociado en un rango de US$ 0.6301 a US$ 1.58 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Lucid Diagnostics?
El ratio precio/beneficio de Lucid Diagnostics es -0.88
¿Cuál es el ratio de efectivo a ventas de Lucid Diagnostics?
El ratio de efectivo a ventas de Lucid Diagnostics es 19.07
¿Cuál es la moneda de reporte de Lucid Diagnostics?
Lucid Diagnostics presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Lucid Diagnostics?
El último ingresos anual de Lucid Diagnostics es USD 2.43M
¿Cuál es el último beneficio anual de Lucid Diagnostics?
El último beneficio anual de Lucid Diagnostics es USD -52.67M
¿Cuál es la dirección registrada de Lucid Diagnostics?
La dirección registrada de Lucid Diagnostics es CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
¿En qué sector industrial opera Lucid Diagnostics?
Lucid Diagnostics opera en el sector SURGICAL,MED INSTR,APPARATUS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MYSZMy Size Inc
US$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.5M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.63M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.84M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
8.58M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
5.96M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.32M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
305.1M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
292.16M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
287.21M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
277.63M

LUCD Discussion

Ver más
georgie18 georgie18 1 mes hace
LUCD...$1.08...Off my .90 alert...🥳

georgie18

Member Level
Re: georgie18 post# 384972

Thursday, November 07, 2024 8:57:15 AM

Post#
385327
of 385451
LUCD...$1.05...🥳...NEW YORK, Nov. 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the manuscript for its multicenter ESOGUARD BE-1 study has been accepted for publication in The American Journal of Gastroenterology, the official journal of the American College of Gastroenterology (ACG). This is the fourth publication presenting clinical validation data for Lucid's EsoGuard® Esophageal DNA Test, and the second to demonstrate its strong performance in an intended-use screening population. Consistent with previous studies, EsoGuard showed high sensitivity and negative predictive value in detecting esophageal precancer (Barrett's Esophagus or BE).

georgie18

Member Level
Re: None

Tuesday, October 29, 2024 9:48:42 AM

Post#
6
of 7
LUCD...9621...Trying Red to Green here...🥳

georgie18

Member Level
Re: None

Tuesday, October 29, 2024 8:23:21 AM

Post#
384965
of 384971
LUCD...90 ...https://schrts.co/DyzNKhGQ ...Break/hold 98 and I think she will rip...🥳
👍️0
chemist72 chemist72 1 mes hace
What is the MoIDX Medicare Program?
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=35025
👍️0
georgie18 georgie18 1 mes hace
LUCD...$1.05...🥳...NEW YORK, Nov. 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the manuscript for its multicenter ESOGUARD BE-1 study has been accepted for publication in The American Journal of Gastroenterology, the official journal of the American College of Gastroenterology (ACG). This is the fourth publication presenting clinical validation data for Lucid's EsoGuard® Esophageal DNA Test, and the second to demonstrate its strong performance in an intended-use screening population. Consistent with previous studies, EsoGuard showed high sensitivity and negative predictive value in detecting esophageal precancer (Barrett's Esophagus or BE).

georgie18

Member Level
Re: None

Tuesday, October 29, 2024 9:48:42 AM

Post#
6
of 7
LUCD...9621...Trying Red to Green here...🥳

georgie18

Member Level
Re: None

Tuesday, October 29, 2024 8:23:21 AM

Post#
384965
of 384971
LUCD...90 ...https://schrts.co/DyzNKhGQ ...Break/hold 98 and I think she will rip...🥳
👍️0
georgie18 georgie18 2 meses hace
LUCD...9621...Trying Red to Green here...🥳

georgie18

Member Level
Re: None

Tuesday, October 29, 2024 8:23:21 AM

Post#
384965
of 384971
LUCD...90 ...https://schrts.co/DyzNKhGQ ...Break/hold 98 and I think she will rip...🥳
👍️0
georgie18 georgie18 2 meses hace
LUCD...90 ...https://schrts.co/DyzNKhGQ ...Break/hold 98 and I think she will rip...🥳
👍️0
Monksdream Monksdream 9 meses hace
LUCD new 52 lo
👍️0
Monksdream Monksdream 1 año hace
LUCD new 52 week low
👍️0
ErnieBilco ErnieBilco 3 años hace
Should have listened to the chart telling me lower but I bought some at $2.39 and $2.21 for a starter. It has a $9+ PT
👍️0
makinezmoney makinezmoney 3 años hace
$LUCD: Not the EV Car Company...............


But you can easily get confused.



Now at $7.30 here in PreMarket



https://www.luciddx.com/





GO $LUCD
👍️0

Su Consulta Reciente

NASDAQ
LUCD
Lucid Diagnostics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados